By: Michael R. Taylor, J.D. Everyone has a stake in the rules that FDA is proposing to strengthen the food safety net in this country. We have reached out far and wide to engage in conversations about the first two … Continue reading →
By: Margaret A. Hamburg, M.D. It has been 11 years since Congress passed the Best Pharmaceuticals for Children Act mandating the creation of the Office of Pediatric Therapeutics (OPT) at FDA. But it has been light years in terms of … Continue reading →
The U.S. Food and Drug Administration (FDA) is alerting health care professionals that the use of the incorrect nonproprietary name for the breast cancer drug Kadcyla (ado-trastuzumab emtansine) in some medication-related electronic systems poses a risk of mix-up with Herceptin (trastuzumab) and may result in medication errors.
The U.S. Food and Drug Administration (FDA) is advising health care professionals and women that the anti-seizure medication valproate sodium and related products, valproic acid and divalproex sodium, are contraindicated and should not be taken by pregnant women for the prevention of migraine headaches.
